ライフサイエンスコーパス: thrombocytopenic purpura

1 ings secreted by/anchored to ECs (thrombotic thrombocytopenic purpura).

2 plasma metalloprotease, leads to thrombotic thrombocytopenic purpura.

3 ances) in the pathogenesis of chronic immune thrombocytopenic purpura.

4 basis for a common bleeding disorder, immune thrombocytopenic purpura.

5 severe, acute and chronic refractory immune thrombocytopenic purpura.

6 e are many definitions for refractory immune thrombocytopenic purpura.

7 splenectomy in patients with chronic immune thrombocytopenic purpura.

8 n used to treat patients with chronic immune thrombocytopenic purpura.

9 -cleaving metalloprotease, causes thrombotic thrombocytopenic purpura.

10 is and targeting treatment of chronic immune thrombocytopenic purpura.

11 management of pregnant patients with immune thrombocytopenic purpura.

12 ne may not be sufficient to cause thrombotic thrombocytopenic purpura.

13 MTS13 activity in plasma leads to thrombotic thrombocytopenic purpura.

14 the diagnostic approach to childhood immune thrombocytopenic purpura.

15 rategies employed in the treatment of immune thrombocytopenic purpura.

16 er clarify its role in idiopathic thrombotic thrombocytopenic purpura.

17 and in an IFN-gamma-enhanced model of immune thrombocytopenic purpura.

18 be treated for these infections, not immune thrombocytopenic purpura.

19 ective means of treating acquired thrombotic thrombocytopenic purpura.

20 arin-induced thrombocytopenia and autoimmune thrombocytopenic purpura.

21 much platelet adhesion may cause thrombotic thrombocytopenic purpura.

22 refractory and relapsing cases of thrombotic thrombocytopenic purpura.

23 hophysiology differs from that of thrombotic thrombocytopenic purpura.

24 refractory and relapsing acquired thrombotic thrombocytopenic purpura.

25 iciency causes a lethal syndrome, thrombotic thrombocytopenic purpura.

26 cal hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

27 ongenital and acquired idiopathic thrombotic thrombocytopenic purpura.

28 gG from a patient with idiopathic thrombotic thrombocytopenic purpura.

29 siology and current management of thrombotic thrombocytopenic purpura.

30 rophic microangiopathic disorder, thrombotic thrombocytopenic purpura.

31 g metalloprotease ADAMTS13 causes thrombotic thrombocytopenic purpura.

32 e illnesses also met criteria for thrombotic thrombocytopenic purpura.

33 large multimers, which may cause thrombotic thrombocytopenic purpura.

34 der clinically indistinguishable from immune thrombocytopenic purpura.

35 days or less before the onset of thrombotic thrombocytopenic purpura.

36 ained after splenectomy for trauma or immune thrombocytopenic purpura.

37 c hypoplasia but not in patients with immune thrombocytopenic purpura.

38 ease occur in patients with acute thrombotic thrombocytopenic purpura.

39 Tpo levels are not elevated in human immune thrombocytopenic purpura.

40 n, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

41 develop a practice guideline for idiopathic thrombocytopenic purpura.

42 nia gravis, pemphigus vulgaris or thrombotic thrombocytopenic purpura.

43 Adamts13(-/-) mice in a model of thrombotic thrombocytopenic purpura.

44 odies against ADAMTS13 that cause thrombotic thrombocytopenic purpura.

45 enic target for autoantibodies in thrombotic thrombocytopenic purpura.

46 , a condition only experienced in thrombotic thrombocytopenic purpura.

47 while ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura.

48 sistance, multiple sclerosis, and idiopathic thrombocytopenic purpura.

49 MPO were characteristic for acute thrombotic thrombocytopenic purpura.

50 eatening disorder called acquired thrombotic thrombocytopenic purpura.

51 mbocytopenia in patients with chronic immune thrombocytopenic purpura.

52 r microangiopathies, particularly thrombotic thrombocytopenic purpura.

53 Among the 130 newly diagnosed patients with thrombocytopenic purpura, 108 (83%; age 43 [30-52]; 73%

54 y was hereditary spherocytosis (111), immune thrombocytopenic purpura (36), sickle cell disease (SCD)

55 Thrombotic thrombocytopenic purpura, a clinical syndrome characteri

56 d a molecular distinction between thrombotic thrombocytopenic purpura, a disease characterized by a l

57 uman endothelial cells and causes thrombotic thrombocytopenic purpura, a disease with similarities to

58 insights into the pathophysiology of immune thrombocytopenic purpura, a disorder in which autoantibo

59 Thrombotic thrombocytopenic purpura, a life-threatening multisystem

60 During therapy of thrombotic thrombocytopenic purpura, a subtype of TMAs often associ

61 loned mAbs from two patients with thrombotic thrombocytopenic purpura and a healthy person.

62 on the status of current research in immune thrombocytopenic purpura and a preview of agents in deve

63 Third, studies on thrombotic thrombocytopenic purpura and ADAMTS13-knockout mice sugg

64 tomy occurred in 82% of patients with immune thrombocytopenic purpura and hematocrit level increased

65 microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome,

66 ation between ticlopidine use and thrombotic thrombocytopenic purpura and other adverse effects, clop

67 us to understand pathogenesis of thrombotic thrombocytopenic purpura and other arterial thromboses a

68 ld be an antithrombotic agent for thrombotic thrombocytopenic purpura and other thrombotic conditions

69 f any treatment for patients with idiopathic thrombocytopenic purpura and persistent severe thrombocy

70 ascular occlusion associated with thrombotic thrombocytopenic purpura and sepsis was revealed by the

71 munoglobulin G from patients with thrombotic thrombocytopenic purpura and sequence alignment of the A

72 ceptable for patients with refractory immune thrombocytopenic purpura and severe thrombocytopenia wit

73 ions including arthritis, cancer, thrombotic thrombocytopenic purpura and the Ehlers-Danlos type VIIC

74 alikes and their distinction from thrombotic thrombocytopenic purpura and the hemolytic uremic syndro

75 Mutations from thrombotic thrombocytopenic purpura and von Willebrand disease prov

76 0% of patients diagnosed with primary immune thrombocytopenic purpura, and are not associated with di

77 rlying Helicobacter pylori-associated immune thrombocytopenic purpura, and Ghevaert et al. describe a

78 are no specific tests that define idiopathic thrombocytopenic purpura, and management decisions are o

79 sis, autoimmune hemolytic anemia, thrombotic thrombocytopenic purpura, and others.

80 gnosis between inherited and acquired immune thrombocytopenic purpura as well as clinical practice on

81 orders, such as rheumatoid arthritis, immune thrombocytopenic purpura, autoimmune hemolytic anemia, s

82 us platelet disorders, especially idiopathic thrombocytopenic purpura, before consideration of therap

83 pathy and a possible diagnosis of thrombotic thrombocytopenic purpura between Jan 8, 2004, and Dec 6,

84 be the most important therapy in thrombotic thrombocytopenic purpura, but clinical data for adjuncti

85 gy published a practice guideline for immune thrombocytopenic purpura, but treatment recommendations

86 ypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, C3GN, and dense deposit diseas

87 Thrombotic thrombocytopenic purpura can occur after the initiation

88 Deaths have been reported for 2.9% of immune thrombocytopenic purpura cases treated with rituximab, b

89 tient suffers from a rare form of idiopathic thrombocytopenic purpura caused by a GPVI-specific autoa

90 hritis, systemic lupus erythematosus, immune thrombocytopenic purpura, chronic cold agglutinin diseas

91 ma exchange in some patients with thrombotic thrombocytopenic purpura; conversely such deficiency is

92 Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare thrombo

93 dying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cleave VWF mu

94 Patients suffering from acquired thrombotic thrombocytopenic purpura develop autoantibodies directed

95 y findings in 11 patients in whom thrombotic thrombocytopenic purpura developed during or soon after

96 vaccine recipients, no excess risk of immune thrombocytopenic purpura diagnosis was detected.

97 and the pathogenesis of clinical thrombotic thrombocytopenic purpura, especially in relation to ADAM

98 Thrombotic thrombocytopenic purpura exemplifies how von Willebrand

99 s for the diagnosis and management of immune thrombocytopenic purpura focused entirely on primary dis

100 re more than 16 years of age, had idiopathic thrombocytopenic purpura for more than 3 months, had a p

101 lasma from 37 patients with acute thrombotic thrombocytopenic purpura had severe deficiency of von Wi

102 of intravenous Rh immune globulin for immune thrombocytopenic purpura has been reported with an estim

103 The treatment landscape of immune thrombocytopenic purpura has the potential for dramatic

104 the pathophysiology of idiopathic thrombotic thrombocytopenic purpura have provided the rationale for

105 itial management of patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-

106 Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-

107 Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-

108 cy, making their distinction from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome diffi

109 ment the reports of occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome durin

110 Case series of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from

111 greatest risk for development of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is ne

112 Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome occur

113 Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome was a

114 women with congenital or familial thrombotic thrombocytopenic purpura-hemolytic uremic syndrome who w

115 crease the risk for occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

116 We present a case report of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/

117 ish aHUS from other TMAs, such as thrombotic thrombocytopenic purpura; however, novel bioassays are b

118 is), 6; hemolytic uremic syndrome-thrombotic thrombocytopenic purpura (HUS/TTP), 8; systemic lupus er

119 penic purpura in children and chronic immune thrombocytopenic purpura in adults.

120 or the treatment of acute and chronic immune thrombocytopenic purpura in children and chronic immune

121 unding the diagnosis and treatment of immune thrombocytopenic purpura in children continue to evolve.

122 nd within 2 weeks of the onset of thrombotic thrombocytopenic purpura in most patients.

123 evision of the present guidelines for immune thrombocytopenic purpura in pregnancy based on evidence-

124 ples of plasma from patients with thrombotic thrombocytopenic purpura in remission or in 74 plasma sa

125 S13 deficiency is associated with thrombotic thrombocytopenic purpura, in which life-threatening epis

126 Hematology and British guidelines on immune thrombocytopenic purpura incidence, prevalence, and natu

127 ia, antiphospholipid syndrome and thrombotic thrombocytopenic purpura, include immunosuppression and

128 n patients with acute episodes of thrombotic thrombocytopenic purpura, independent of ADAMTS13 activi

129 cidence of ticlopidine-associated thrombotic thrombocytopenic purpura is 1 per 1600 to 5000 patients

130 Idiopathic thrombocytopenic purpura is a common acquired bleeding d

131 Treatment of chronic refractory idiopathic thrombocytopenic purpura is a dilemma because many patie

132 Thrombotic thrombocytopenic purpura is a potentially fatal disease

133 The diagnosis of immune thrombocytopenic purpura is a process of elimination of

134 Thrombotic thrombocytopenic purpura is a rare complication of thien

135 Thrombotic thrombocytopenic purpura is associated with acquired or

136 The acquired form of thrombotic thrombocytopenic purpura is associated with inhibitory a

137 Thrombotic thrombocytopenic purpura is caused by congenital or acqu

138 e onset of ticlopidine-associated thrombotic thrombocytopenic purpura is difficult to predict, despit

139 ed by thrombotic microangiopathy, thrombotic thrombocytopenic purpura is distinguished by a severe de

140 ing protease activity in acquired thrombotic thrombocytopenic purpura is due to an autoantibody inhib

141 Because the incidence of idiopathic thrombocytopenic purpura is greatest in young women, its

142 If the diagnosis of immune thrombocytopenic purpura is in question due to the prese

143 Refractory immune thrombocytopenic purpura is infrequent in children, but

144 about the incidence and prevalence of immune thrombocytopenic purpura is limited, with nearly all dat

145 l investigation of novel therapies in immune thrombocytopenic purpura is undergoing a revolution that

146 d between ChAdOx1 vaccination and idiopathic thrombocytopenic purpura (ITP) (0-27 d after vaccination

147 Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platele

148 ction in North American patients with immune thrombocytopenic purpura (ITP) and the effect of H pylor

149 ine if megakaryocytes are targeted by immune thrombocytopenic purpura (ITP) autoantibodies, as are pl

150 treatment for adult patients with idiopathic thrombocytopenic purpura (ITP) for more than 50 years.

151 marrow patient and a patient with Idiopathic Thrombocytopenic Purpura (ITP) for the same platelet con

152 The basis of treatment for immune thrombocytopenic purpura (ITP) has conventionally relied

153 Most patients with chronic immune thrombocytopenic purpura (ITP) have autoantibodies direc

154 Guidelines for management of acute immune thrombocytopenic purpura (ITP) in childhood were publish

155 The pathogenesis of chronic idiopathic thrombocytopenic purpura (ITP) involves antibody-mediate

156 Idiopathic thrombocytopenic purpura (ITP) is a common hematologic d

157 Adult chronic immune thrombocytopenic purpura (ITP) is a common hematologic d

158 Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disease

159 Adult chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder

160 Chronic immune thrombocytopenic purpura (ITP) is characterised by accel

161 Chronic immune thrombocytopenic purpura (ITP) is characterized by low p

162 Immune thrombocytopenic purpura (ITP) is characterized by the p

163 Chronic immune thrombocytopenic purpura (ITP) is manifested by autoanti

164 Idiopathic thrombocytopenic purpura (ITP) is the most common acquir

165 Although idiopathic thrombocytopenic purpura (ITP) is the most common autoim

166 Patients with severe immune thrombocytopenic purpura (ITP) may require an acute incr

167 FcgammaR-dependent cytopenias such as immune thrombocytopenic purpura (ITP) or autoimmune hemolytic a

168 Treatments for immune thrombocytopenic purpura (ITP) providing durable platele

169 somes as a new treatment strategy for immune thrombocytopenic purpura (ITP) through the use of a mous

170 allow adults with recently diagnosed immune thrombocytopenic purpura (ITP) who had failed an initial

171 of immune-related diseases, including immune thrombocytopenic purpura (ITP), autoimmune neuropathies,

172 Indications were idiopathic thrombocytopenic purpura (ITP), hereditary spherocytosis

173 ites in 23 countries with chronic idiopathic thrombocytopenic purpura (ITP), platelet counts less tha

174 destructive disorders, including idiopathic thrombocytopenic purpura (ITP), posttransfusion purpura

175 s, the authors concluded that, in idiopathic thrombocytopenic purpura (ITP), production of platelets

176 ment of children newly diagnosed with immune thrombocytopenic purpura (ITP).

177 ) on March 24, 1995, for treatment of immune thrombocytopenic purpura (ITP).

178 in platelet kinetics associated with immune thrombocytopenic purpura (ITP).

179 in March 1995 to treat patients with immune thrombocytopenic purpura (ITP).

180 the standard first-line treatment for immune thrombocytopenic purpura (ITP).

181 in-induced thrombocytopenia (HIT) and immune thrombocytopenic purpura (ITP).

182 er system was developed in a model of immune thrombocytopenic purpura (ITP).

183 s as well as in >80% of patients with immune thrombocytopenic purpura (ITP).

184 adult patients (n = 137) with classic immune thrombocytopenic purpura (ITP; n = 156) or human immunod

185 Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led

186 asma samples from immune-mediated thrombotic thrombocytopenic purpura (iTTP) patients.

187 ary for the development of immune thrombotic thrombocytopenic purpura (iTTP).

188 he acute phase of immune-mediated thrombotic thrombocytopenic purpura (iTTP).

189 ith increased mortality in immune thrombotic thrombocytopenic purpura (iTTP).

190 ancreas/kidney (SPK)] developed a thrombotic thrombocytopenic purpura-like clinical syndrome.

191 ell-characterized murine model of autoimmune thrombocytopenic purpura, male (NZW x BXSB) F1 mice (W/B

192 eral systemic diseases, including thrombotic thrombocytopenic purpura, manifest much of their patholo

193 A diagnosis of immune thrombocytopenic purpura may be based on an evaluation o

194 ts, hypertension (n = 2) and immune-mediated thrombocytopenic purpura (n = 1), were possibly related

195 = 27), neurotoxicity (n = 9) and thrombotic thrombocytopenic purpura (n = 2).

196 management decisions in suspected thrombotic thrombocytopenic purpura, new evidence supporting the ef

197 of the pathological mechanisms of thrombotic thrombocytopenic purpura not only provide a rationale fo

198 Management of refractory immune thrombocytopenic purpura often requires multiple agents

199 ts and children with acute or chronic immune thrombocytopenic purpura or HIV-related thrombocytopenia

200 sseminated intravascular coagulation, immune thrombocytopenic purpura, or splenic sequestration did n

201 as a second-line treatment of chronic immune thrombocytopenic purpura outside a clinical trial.

202 n plasma from patients with acute thrombotic thrombocytopenic purpura, patients with other diseases,

203 es to be indicated for idiopathic thrombotic thrombocytopenic purpura regardless of ADAMTS13 levels,

204 urring in patients with inherited thrombotic thrombocytopenic purpura, resulted in a significant redu

205 associated with diseases such as thrombotic thrombocytopenic purpura, sepsis, and diabetes among oth

206 f delivery of a pregnant patient with immune thrombocytopenic purpura should be determined based on m

207 oglobulin preparation in treatment of immune thrombocytopenic purpura suggests that other mechanisms

208 receiving alemtuzumab developed late immune thrombocytopenic purpura that remitted with standard the

209 In thrombotic thrombocytopenic purpura, the clinical impact of ADAMTS1

210 d with myelodysplastic syndromes, idiopathic thrombocytopenic purpura, thrombocytopenia due to human

211 rotease predisposes patients with thrombotic thrombocytopenic purpura to platelet thrombosis.

212 Thrombotic thrombocytopenic purpura (TTP) affects 1 in 1600 to 1 in

213 ich includes two major disorders: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic synd

214 Acquired thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic synd

215 Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic synd

216 Thrombotic thrombocytopenic purpura (TTP) and sporadic hemolytic-ur

217 Thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic

218 Recovery from acute episodes of thrombotic thrombocytopenic purpura (TTP) appears complete except f

219 leading to idiopathic, autoimmune thrombotic thrombocytopenic purpura (TTP) by identifying naturally

220 The pathophysiology of thrombotic thrombocytopenic purpura (TTP) can be explained by the a

221 eceived a diagnosis of hereditary thrombotic thrombocytopenic purpura (TTP) due to severe ADAMTS13 de

222 haemolytic uraemic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP) during an Escherichia col

223 Thrombotic thrombocytopenic purpura (TTP) has been a mysterious and

224 Thrombotic thrombocytopenic purpura (TTP) in adults is usually caus

225 Its aims are: to rule thrombotic thrombocytopenic purpura (TTP) in or out, with urgency,

226 Thrombotic thrombocytopenic purpura (TTP) is a devastating thrombot

227 Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-threatening dis

228 Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening dis

229 Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening dis

230 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening dis

231 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening hem

232 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening ill

233 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening sys

234 Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic dis

235 Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threat

236 Thrombotic thrombocytopenic purpura (TTP) is a rare and often fatal

237 Gemcitabine-associated thrombotic thrombocytopenic purpura (TTP) is a rare complication of

238 Thrombotic thrombocytopenic purpura (TTP) is a syndrome with numero

239 Idiopathic thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangi

240 Thrombotic thrombocytopenic purpura (TTP) is an acute, life-threate

241 Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation

242 Acquired thrombotic thrombocytopenic purpura (TTP) is characterized by throm

243 The pathogenesis of thrombotic thrombocytopenic purpura (TTP) is obscure.

244 Thrombotic thrombocytopenic purpura (TTP) is primarily caused by im

245 Thrombotic thrombocytopenic purpura (TTP) is the common name for ad

246 Acquired thrombotic thrombocytopenic purpura (TTP) is the consequence of a s

247 Hereditary thrombotic thrombocytopenic purpura (TTP) may be rare, but it is fo

248 (APS), atypical presentations of thrombotic thrombocytopenic purpura (TTP) or heparin-induced thromb

249 factor (VWF)-cleaving protease implicated in thrombocytopenic purpura (TTP) pathogenesis was identifi

250 c ADAMTS13 activity in congenital thrombotic thrombocytopenic purpura (TTP) patients is constrained b

251 In contrast to thrombotic thrombocytopenic purpura (TTP) patients, no aHUS patient

252 mal plasma, and its deficiency in thrombotic thrombocytopenic purpura (TTP) patients, provides additi

253 Although both aHUS and acquired thrombotic thrombocytopenic purpura (TTP) remain clinical diagnoses

254 ive treatment, most patients with thrombotic thrombocytopenic purpura (TTP) survive the acute TTP epi

255 Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery for over ha

256 activity is the primary cause of thrombotic thrombocytopenic purpura (TTP) whereas overwhelming acti

257 f plasma ADAMTS13 activity causes thrombotic thrombocytopenic purpura (TTP), a life-threatening syndr

258 key factor in the pathogenesis of thrombotic thrombocytopenic purpura (TTP), a life-threatening throm

259 In thrombotic thrombocytopenic purpura (TTP), a multimeric form of von

260 In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated defic

261 n effective empiric treatment for thrombotic thrombocytopenic purpura (TTP), but how therapy affects

262 may precipitate acute episodes of thrombotic thrombocytopenic purpura (TTP), but pregnancy outcomes i

263 d to a life-threatening disorder, thrombotic thrombocytopenic purpura (TTP), characterized by platele

264 t advances have demonstrated that thrombotic thrombocytopenic purpura (TTP), characterized by widespr

265 ted with platelet transfusions in thrombotic thrombocytopenic purpura (TTP), heparin-induced thromboc

266 aHUS from other TMAs, especially thrombotic thrombocytopenic purpura (TTP), is difficult due to over

267 immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP), respectively, illuminate

268 molytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), the histories and presen

269 In acquired thrombotic thrombocytopenic purpura (TTP), the persistence of sever

270 d our understanding of idiopathic thrombotic thrombocytopenic purpura (TTP).

271 stic of idiopathic and HIV-linked thrombotic thrombocytopenic purpura (TTP).

272 ts with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP).

273 3) revolutionized our approach to thrombotic thrombocytopenic purpura (TTP).

274 etalloprotease is associated with thrombotic thrombocytopenic purpura (TTP).

275 activity of the protease, causes thrombotic thrombocytopenic purpura (TTP).

276 ssociated with the development of thrombotic thrombocytopenic purpura (TTP).

277 ombosis in patients with acquired thrombotic thrombocytopenic purpura (TTP).

278 systemic platelet aggregation in thrombotic thrombocytopenic purpura (TTP).

279 to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

280 Pregnancy can precipitate thrombotic thrombocytopenic purpura (TTP).

281 iency to complement activation in thrombotic thrombocytopenic purpura (TTP).

282 eatening disorder called acquired thrombotic thrombocytopenic purpura (TTP).

283 molytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP).

284 iency leads to the fatal disorder thrombotic thrombocytopenic purpura (TTP).

285 pts to ameliorate the symptoms of thrombotic thrombocytopenic purpura (TTP).

286 ucial role in the pathogenesis of thrombotic thrombocytopenic purpura (TTP).

287 t life-threatening disease called thrombotic thrombocytopenic purpura (TTP).

288 of this enzyme activity leads to thrombotic thrombocytopenic purpura (TTP).

289 severe deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura (TTP).

290 to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

291 le in pathogenesis of the disease thrombotic thrombocytopenic purpura (TTP); however, experimental ev

292 TTP cases from the United Kingdom Thrombotic Thrombocytopenic Purpura (UK TTP) Registry with clinical

293 ssociated with the development of thrombotic thrombocytopenic purpura, usually within 1 month of init

294 stances of ticlopidine-associated thrombotic thrombocytopenic purpura were identified.

295 In secondary forms of immune thrombocytopenic purpura, when the hematologist plays a

296 A more common TMA is thrombotic thrombocytopenic purpura, which is caused by the lack of

297 However, patients with chronic idiopathic thrombocytopenic purpura who harbor predominantly young

298 Adults with severe thrombocytopenic purpura who responded poorly to therape

299 itors, and the risk of relapse of thrombotic thrombocytopenic purpura will be important to further va

300 ease platelet counts in patients with immune thrombocytopenic purpura, without significant adverse ef